ES2122289T3 - Derivados de 5-arilindol. - Google Patents

Derivados de 5-arilindol.

Info

Publication number
ES2122289T3
ES2122289T3 ES94918494T ES94918494T ES2122289T3 ES 2122289 T3 ES2122289 T3 ES 2122289T3 ES 94918494 T ES94918494 T ES 94918494T ES 94918494 T ES94918494 T ES 94918494T ES 2122289 T3 ES2122289 T3 ES 2122289T3
Authority
ES
Spain
Prior art keywords
sub
compounds
independently
ring
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94918494T
Other languages
English (en)
Inventor
John E Macor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of ES2122289T3 publication Critical patent/ES2122289T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPUESTOS DE LA FORMULA (I), EN LA QUE A, B, D, E Y F SON CADA UNO, INDEPENDIENTEMENTE, NITROGENO O CARBONO; R{SUB,1} ES HIDROGENO, ALQUILO C{SUB,1} A C{SUB,6}, (CH{SUB,2}{SUB,N}R{SUB,7}, O ALQUILARILO C{SUB,1} A C{SUB,3}; R{SUB,2}, R{SUB,3}, R{SUB,4}, R{SUB,5} Y R{SUB,6} SON CADA UNO, INDEPENDIENTEMENTE, HIDROGENO, ALQUILO C{SUB,1} A C{SUB,6}, ARILO, ALQUILARILO C{SUB,1} A C{SUB,3}, HALOGENO, CIANO, NITRO, (CH{SUB,2}){SUB,M}NR{SUB,8}R{SUB,9}, (CH{SUB,2}){SUB,M}OR{SUB,9}, -SR{SUB,9}, SO{SUB,2}NR{SUB,8}R{SUB,9}, (CH{SUB,2}){SUB,M}NR{SUB,8}SO{SUB,2}R{SUB,9}, (CH{SUB,2}){SUB,M}NR{SUB,8}CO{SUB,2}R{SUB,9}, (CH{SUB,2}){SUB,M}NR{SUB,8}COR{SUB,9,}, (CH{SUB,2}){SUB,M}CONR{SUB,7}R{SUB,9} O (CH{SUB,2}){SUB,M}CO{SUB,2}R{SUB,9}; R{SUB,2} Y R{SUB,3}, R{SUB,3} Y R{SUB,4}, R{SUB,4} Y R{SUB,5}, Y R{SUB,5} Y R{SUB,6} SE PUEDEN TOMAR JUNTOS PARA FORMAR UN ANILLO DE ALQUILO DE 5 A 7 ELEMENTOS, UN ANILLO DE ARILO DE 6 ELEMENTOS, UN ANILLO DE HETEROALQUILO DE 5 A 7 ELEMENTOS, QUE TIENE 1 HETEROATOMO DE N, O O S, O UN ANILLO DE HETEROARILO DE 5 A 6 ELEMENTOS QUE TIENE 1 O 2 HETEROATOMOS DE N, O O S; R{SUB,7} ES -OR{SUB,10}, SR{SUB,10}, -SO{SUB,2}NR{SUB,10}R{SUB,11}, NR{SUB,10}SO{SUB,2}R{SUB,11}, -NR{SUB,10}CO{SUB,2}R{SUB,11}, NR{SUB,10}COR{SUB,11}, -CONR{SUB,10}R{SUB,11} O CO{SUB,2}R{SUB,10}; R{SUB,8}, R{SUB,9}, R{SUB,10} Y R{SUB,11} SON CADA UNO, INDEPENDIENTEMENTE, HIDROGENO, ALQUILO C{SUB,1} A C{SUB,6} O ALQUILARILO C{SUB,1} A C{SUB,6}; M ES 0, 1 O 2; N ES 2, 3 O 4; Y LOS GRUPOS ARILO DE ARRIBA Y LAS ESTRUCTURAS DE ARILO DE LOS GRUPOS ALQUILARILO DE ARRIBA SON CADA UNO, INDEPENDIENTEMENTE, FENILO O FENILO SUSTITUIDO, EN DONDE DICHO FENILO SUSTITUIDO PUEDE SER SUSTITUIDO POR DE 1 A 3 DE ENTRE EL ALQUILO C{SUB,1} A C{SUB,4}, HALOGENO, HIDROXI, CIANO, CARBOXAMIDO, NITRO O ALCOXI C{SUB,1} A C{SUB,4}, Y LAS SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS. ESTOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO DE LA MIGRAÑA Y DE OTROS TRASTORNOS Y SON NUEVOS. ESTOS COMPUESTO SON AGENTES PSICOTERAPEUTICOS UTILES Y SON POTENTES AGONISTAS DE LA SEROTONINA (5-HT{SUB,1}) Y SE PUEDEN UTILIZAR PARA EL TRATAMIENTO DE LA DEPRESION, ANSIEDAD, TRASTORNOS DEL APETITO, OBESIDAD, ABUSO DE FARMACOS, DOLORES DE CABEZA LOCALIZADOS, MIGRAÑA, DOLOR Y HERMICRANIA PAROXISTICA CRONICA Y DOLOR DE CABEZA ASOCIADO A TRASTORNOS VASCULARES, Y OTROS TRASTORNOS DEBIDOS A UNA NEUROTRANSMISION SEROTONERGICA DEFICIENTE. LOS COMPUESTOS TAMBIEN SE PUEDEN UTILIZAR COMO ANTIHIPERTENSIVOS Y VASODILATADORES DE ACCION CENTRAL.
ES94918494T 1993-08-31 1994-07-04 Derivados de 5-arilindol. Expired - Lifetime ES2122289T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11528293A 1993-08-31 1993-08-31

Publications (1)

Publication Number Publication Date
ES2122289T3 true ES2122289T3 (es) 1998-12-16

Family

ID=22360355

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94918494T Expired - Lifetime ES2122289T3 (es) 1993-08-31 1994-07-04 Derivados de 5-arilindol.

Country Status (26)

Country Link
US (3) US5849739A (es)
EP (1) EP0716649B1 (es)
JP (1) JP2860603B2 (es)
KR (1) KR100191973B1 (es)
CN (1) CN1129933A (es)
AT (1) ATE170836T1 (es)
AU (1) AU686654B2 (es)
BR (1) BR9407402A (es)
CA (1) CA2169179C (es)
CO (1) CO4230238A1 (es)
CZ (1) CZ59996A3 (es)
DE (1) DE69413240T2 (es)
DK (1) DK0716649T3 (es)
EC (1) ECSP941122A (es)
EG (1) EG20547A (es)
ES (1) ES2122289T3 (es)
FI (1) FI113536B (es)
HU (1) HUT75646A (es)
IL (1) IL110773A (es)
MY (1) MY111127A (es)
NO (1) NO960818D0 (es)
NZ (1) NZ267487A (es)
PE (1) PE11895A1 (es)
PL (1) PL177604B1 (es)
WO (1) WO1995006636A1 (es)
ZA (1) ZA946608B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
CN1129933A (zh) * 1993-08-31 1996-08-28 辉瑞大药厂 5-芳基吲哚衍生物
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
EP0844996A1 (en) * 1995-08-07 1998-06-03 MERCK SHARP & DOHME LTD. Substituted 1-indolylpropyl-4-phenethylpiperazine derivatives
EP1003738B1 (en) * 1997-08-09 2003-11-19 SmithKline Beecham plc Bicyclic compounds as ligands for 5-ht1 receptors
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
AU3170099A (en) * 1998-04-16 1999-11-08 Yamanouchi Pharmaceutical Co., Ltd. Remedies for obesity
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
GB0124934D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
DE10159922A1 (de) * 2001-12-06 2003-06-26 Gruenenthal Gmbh Substituierte 2-Pyrrolidin-2-yl-1H-indol-Derivate
JP4472349B2 (ja) 2002-02-12 2010-06-02 スミスクライン ビーチャム コーポレーション ｐ３８阻害薬として有用なニコチンアミド誘導体
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308201D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0318814D0 (en) 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
WO2005066157A1 (en) * 2004-01-02 2005-07-21 Suven Life Sciences 3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators
US7223994B2 (en) * 2004-06-03 2007-05-29 International Business Machines Corporation Strained Si on multiple materials for bulk or SOI substrates
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US10590083B2 (en) 2017-08-10 2020-03-17 Janssen Pharmaceutica Nv Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists
US10336701B2 (en) 2017-08-10 2019-07-02 Janssen Pharmaceutica Nv Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists
US10399944B2 (en) 2017-08-10 2019-09-03 Janssen Pharmaceutica Nv Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2773875A (en) * 1952-03-28 1956-12-11 Hoffmann La Roche Indole derivatives and method for producing same
GB886684A (en) * 1957-09-17 1962-01-10 Upjohn Co Improvements in or relating to heterocyclic compounds and the manufacture thereof
GB851780A (en) * 1958-02-25 1960-10-19 Rhone Poulenc Sa New indole derivatives
US3037031A (en) * 1959-08-04 1962-05-29 Warner Lambert Pharmaceutical Derivatives of 3-(2-aminoalkyl)-5-indolol and process therefor
GB893707A (en) * 1960-03-01 1962-04-11 Roche Products Ltd Novel tryptamine derivatives and a process for the manufacture thereof
GB966562A (en) * 1961-04-06 1964-08-12 Parke Davis & Co Amine compounds and means of producing the same
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
SI9111010B (sl) * 1990-06-07 2005-02-28 Astrazeneca Ab 3,5-disubstituirani indolni derivati kot "5-HT1-podobni" receptorski agonisti
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
PL168919B1 (pl) * 1990-10-15 1996-05-31 Pfizer Sposób wytwarzania nowych pochodnych indolu PL PL PL PL
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5208248A (en) * 1991-01-11 1993-05-04 Merck Sharpe & Dohme, Ltd. Indazole-substituted five-membered heteroaromatic compounds
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
CA2124206C (en) * 1991-11-25 2001-02-27 John Eugene Macor Indole derivatives
GB9201038D0 (en) * 1992-01-16 1992-03-11 Glaxo Group Ltd Chemical compounds
US5409941A (en) * 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives
TW288010B (es) * 1992-03-05 1996-10-11 Pfizer
RU2101283C1 (ru) * 1992-04-07 1998-01-10 Пфайзер Инк. Производные индола или их фармацевтически приемлемые соли
GB9207930D0 (en) * 1992-04-10 1992-05-27 Pfizer Ltd Indoles
AU670270B2 (en) * 1992-04-10 1996-07-11 Pfizer Inc. Acylaminoindole derivatives as 5-HT1 agonists
GB9208161D0 (en) * 1992-04-14 1992-05-27 Pfizer Ltd Indoles
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
TW251284B (es) * 1992-11-02 1995-07-11 Pfizer
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
HUT73807A (en) * 1993-04-22 1996-09-30 Pfizer Res & Dev 5-ht1-like indole derivatives and pharmaceutical compositions containing them
AP486A (en) * 1993-04-27 1996-04-16 Pfizer Indole derivatives.
CN1129933A (zh) * 1993-08-31 1996-08-28 辉瑞大药厂 5-芳基吲哚衍生物

Also Published As

Publication number Publication date
ATE170836T1 (de) 1998-09-15
HU9600509D0 (en) 1996-04-29
IL110773A (en) 2001-06-14
BR9407402A (pt) 1996-11-05
CZ59996A3 (en) 1996-06-12
JPH08511032A (ja) 1996-11-19
CN1129933A (zh) 1996-08-28
FI943976A7 (fi) 1995-03-01
EP0716649B1 (en) 1998-09-09
WO1995006636A1 (en) 1995-03-09
PL313227A1 (en) 1996-06-10
CO4230238A1 (es) 1995-10-19
ZA946608B (en) 1996-02-28
PL177604B1 (pl) 1999-12-31
AU6979694A (en) 1995-03-22
NO960818L (no) 1996-02-28
CA2169179A1 (en) 1995-03-09
PE11895A1 (es) 1995-05-12
FI113536B (fi) 2004-05-14
NZ267487A (en) 1997-09-22
FI943976A0 (fi) 1994-08-30
US5942524A (en) 1999-08-24
DK0716649T3 (da) 1999-02-08
EG20547A (en) 1999-07-31
KR100191973B1 (ko) 1999-06-15
IL110773A0 (en) 1999-04-11
US5849739A (en) 1998-12-15
EP0716649A1 (en) 1996-06-19
NO960818D0 (no) 1996-02-28
CA2169179C (en) 2000-02-29
US6093822A (en) 2000-07-25
MY111127A (en) 1999-08-30
HUT75646A (en) 1997-05-28
ECSP941122A (es) 1994-12-15
KR960704843A (ko) 1996-10-09
JP2860603B2 (ja) 1999-02-24
AU686654B2 (en) 1998-02-12
DE69413240T2 (de) 1999-02-04
DE69413240D1 (en) 1998-10-15

Similar Documents

Publication Publication Date Title
ES2122289T3 (es) Derivados de 5-arilindol.
ES2160596T3 (es) Derivados de quinuclidina como antagonistas de la sustancia p.
ES2083569T3 (es) Nuevos derivados de ariletenileno y procedimiento para su preparacion.
ES2158314T3 (es) Oximas, hidrazonas y olefinas sustituidas como antagonistas de la neuroquinina.
ES2164758T3 (es) Derivados de morfolina sustituidos y su uso como agentes terapeuticos.
ES2108425T3 (es) Analogos de atp sustituidos con n-alquilo-2.
ES2094653T3 (es) Derivados de indol como antagonistas de tipo 5-ht1 para uso en la migraña.
ES2097496T3 (es) Derivados acilaminoindol como agonistas de 5-ht1.
PE20000467A1 (es) Derivado de indol util como inhibidor de serotonina
PA8580301A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
ES2116583T3 (es) Compuestos azaciclicos, composiciones que los contienen y su uso como antagonistas de taquicininas.
AR035479A1 (es) Derivados de eteres biarilicos y sus sales, composiciones farmaceuticas que los comprenden y procedimientos para el tratamiento de trastornos o afecciones
ES2188666T3 (es) Analogos de la distamicina utilies como agentes antitumorales o antivirales.
ES2150567T3 (es) Antagonistas del factor de liberacion de la corticotropina.
ES2161231T3 (es) Compuestos heterociclicos como antagonistas de bradiquinina.
ES2127919T3 (es) 4-amino-piridinas, procedimiento para su preparacion, asi como medicamentos que contienen estos compuestos.
AR004320A1 (es) Nuevos compuestos de pirimidina condensados biciclicos; un procedimiento para su preparacion; composiciones farmaceuticas que los contienen y su usocomo agentes terapeuticos, en particular como inhibidores de la tirosina quinasa.
ES2062460T3 (es) Nuevos derivados de la isoindolona, su preparacion y las composiciones farmaceuticas que les contienen.
ES2151652T3 (es) Derivados de indol como antagonistas del receptor 5ht.
AR008829A1 (es) Derivados 6,6- o 6,7 biciclicos sustituidos que contienen pirido o pirimido como agentes antagonistas para el tratamiento de enfermedades gastrointestinales, inflamatorias y del snc, y composicion farmaceutica
ES2064973T3 (es) Nuevos derivados de indol.
CO4970728A1 (es) 2-aminopiridinas que contienen sustituyentes de anillos condensados
AR035957A1 (es) Procedimiento para la preparacion de indenos 1,3-sustituidos y compuestos azapoliciclicos condensados con arilos
ES2176199T3 (es) Derivados de indol como agonistas de s-ht1.
AR013153A1 (es) Derivados de 2-arildihidropirimidina, proceso para su preparacion, composiciones farmaceuticas que contienen dichos derivados, y el uso de dichosderivados y composiciones como ligandos para canales de calcio neuronales de tipo n.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 716649

Country of ref document: ES